T1D is the clinical outcome of a relapsing-remitting T-cell driven autoimmunity that, across three stages, gradually impairs and damages a mass of pancreatic β cells that requires exogenous insulin replacement to maintain normoglycemia (23, 24). Here, INS is linked to Autoimmunity.